Evidence mapPaperPMID 41977331Full record

ArticleInternational journal of molecular sciences2026

The Role of the HMGB1 C-Terminal Domain in Epithelial-Mesenchymal Transition and Invasion in 2D and 3D MDA-MB-231 Breast Cancer Models.

Desislava Vladimirova, Shazie Yusein-Myashkova, Evdokia Pasheva, Iva Ugrinova, Jordana Todorova

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Desislava VladimirovaInstitute of Molecular Biology "Acad. Roumen Tsanev", Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
Shazie Yusein-MyashkovaInstitute of Molecular Biology "Acad. Roumen Tsanev", Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.ORCID 0000-0002-0573-5685
Evdokia PashevaInstitute of Molecular Biology "Acad. Roumen Tsanev", Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
Iva UgrinovaInstitute of Molecular Biology "Acad. Roumen Tsanev", Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.ORCID 0000-0002-0116-0079
Jordana TodorovaInstitute of Molecular Biology "Acad. Roumen Tsanev", Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.

Funding

Bulgarian national scientific fund KΠ-06-H51/13
6 · The paper itself

Abstract

High-mobility group box 1 (HMGB1) is a multifunctional protein that operates both within the nucleus and as an extracellular signaling molecule. Its extracellular activity has been increasingly associated with cancer progression. Emerging evidence suggests that structural modifications of HMGB1, including C-terminal truncation, may alter its biological activity, though the underlying mechanisms remain largely unexplored. Here, we show that HMGB1, which lacks the entire C-terminal acidic tail, is associated with increased cellular plasticity and invasive potential through distinct signaling pathways not strictly dependent on RAGE (Receptor for Advanced Glycation End-product) under the tested conditions. Functional analyses indicate that this truncated form promotes epithelial-mesenchymal transition-related behaviors and activates downstream inflammatory signaling in a context-dependent manner. Notably, pharmacological intervention with metformin effectively suppressed responses to the full-length protein but was less effective against the tail-less variant, underscoring potential therapeutic challenges. These findings suggest an underappreciated regulatory role of the HMGB1 C-terminal domain in tumor aggressiveness.

Indexed as

Breast NeoplasmsEpithelial-Mesenchymal TransitionHMGB1 ProteinCell MovementFemaleHumansMDA-MB-231 CellsMetforminNeoplasm InvasivenessProtein DomainsReceptor for Advanced Glycation End ProductsSignal TransductionHMGB1 ProteinHMGB1 protein, humanMetforminReceptor for Advanced Glycation End Products3D spheroid modelepithelial-to-mesenchymal transition (EMT)HMGB1HMGB1ΔCmetforminRAGE

Identifiers

PMID41977331
PMCPMC13072789

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.